Revive Therapeutics Provides Update on its Cannabis-based Pharmaceuticals Initiatives

TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabis-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for unmet medical needs and rare diseases.

“As part of our pharmaceutical strategy, we are focusing our efforts on developing unique cannabis-based therapies for rare diseases,” said Fabio Chianelli, President of Revive.  “We are pursuing strategies that we believe will result in lower development costs, faster-time-to-market, and market exclusivity for our cannabis-based pharmaceutical products.  We believe by securing patent protection and/or orphan drug status, and establishing proof-of-concept in validated pre-clinical models may expedite the clinical development and regulatory pathway of our products and pave the way for partnering with pharmaceutical companies and licensed producers of

... read more at: